INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 128 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2016. The put-call ratio across all filers is 3.16 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $67,000 | -60.8% | 4,398 | 0.0% | 0.01% | -62.1% |
| Q2 2016 | $171,000 | +59.8% | 4,398 | +14.3% | 0.03% | +52.6% |
| Q1 2016 | $107,000 | -6.1% | 3,848 | +80.9% | 0.02% | -5.0% |
| Q4 2015 | $114,000 | +34.1% | 2,127 | 0.0% | 0.02% | +17.6% |
| Q3 2015 | $85,000 | +25.0% | 2,127 | 0.0% | 0.02% | +30.8% |
| Q2 2015 | $68,000 | – | 2,127 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |